Tripep's RAS Technology and the German Biotech Company Cosmix' mRNA Display Technology Will Be Co-Developed in the New US Company, Opsonics Therapeutics Inc.
Published: Aug 25, 2009
STOCKHOLM, Sweden--(BUSINESS WIRE)--Tripep (STO:TPEP) and the German biotech company Cosmix AG have both licensed their respective technologies (RAS and mRNA Display Library) to a newly formed US company named Opsonic Therapeuticals Inc. within which Tripep’s RAS technology will be developed. The RAS technology is based on oligosaccharide linked peptides that can redirect natural antibodies present in all humans to new targets. Cosmix in turn has developed the mRNA Display Library technology by which peptides that binds to a selected target rapidly are identified. Opsonic will use Cosmix technology to identify target-binding peptides and these are then used in RAS peptides aimed for therapeutic use.